MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
BioNano Genomics General and Administrative Expenses 2011-2025 | BNGO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses BioNano Genomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.9 M | 92.8 M | 88.6 M | 58.5 M | 31.1 M | 20.2 M | 14.2 M | 14.1 M | 13 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 92.8 M | 13 M | 42.7 M |
Quarterly General and Administrative Expenses BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.06 M | 8.35 M | 9.03 M | - | 9.46 M | 11.6 M | 19.1 M | - | 24.9 M | 26.9 M | 26 M | - | 21.2 M | 21.8 M | 20.3 M | - | 15.3 M | 13.8 M | 9.53 M | - | 8.66 M | 5.61 M | 7.37 M | - | 4.45 M | 5.06 M | 4.79 M | - | 3.22 M | 3.49 M | 2.9 M | - | 3.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.9 M | 2.9 M | 11.8 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
5.78 M | $ 17.27 | 1.8 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 15.82 | 0.44 % | $ 170 M |  China |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
DarioHealth Corp.
DRIO
|
18.1 M | $ 12.14 | 2.1 % | $ 344 M | Israel |
 |
DexCom
DXCM
|
1.19 B | $ 65.83 | -1.69 % | $ 25.4 B | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 39.06 | 1.11 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Exact Sciences Corporation
EXAS
|
191 M | $ 101.64 | 0.14 % | $ 18.8 B | USA |
 |
Danaher Corporation
DHR
|
7.76 B | $ 227.72 | 0.54 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 27.0 | -0.52 % | $ 816 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
118 M | $ 19.98 | -2.82 % | $ 1.07 B | USA |
 |
Celcuity
CELC
|
9.06 M | $ 101.67 | -3.4 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
7.44 M | $ 3.3 | -7.82 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
14.3 M | $ 0.29 | -14.47 % | $ 8.51 M | USA |
 |
IQVIA Holdings
IQV
|
1.99 B | $ 222.75 | 0.24 % | $ 40.4 B | USA |
 |
Guardant Health
GH
|
180 M | $ 103.7 | 1.6 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 134.4 | -0.35 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
751 M | $ 197.62 | 2.4 % | $ 10.2 B | USA |
 |
Quotient Limited
QTNT
|
37.4 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Mettler-Toledo International
MTD
|
936 M | $ 1 410.02 | 1.15 % | $ 29.9 B | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 183.96 | 0.79 % | $ 20.4 B | USA |
 |
NeoGenomics
NEO
|
260 M | $ 12.03 | 1.48 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
218 M | $ 6.85 | -0.22 % | $ 1.49 B | USA |
|
Biodesix
BDSX
|
80.5 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
276 M | $ 7.04 | -2.36 % | $ 638 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 262.89 | -0.48 % | $ 22.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 184.38 | -1.18 % | $ 15.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
442 M | $ 698.77 | -0.77 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
194 M | $ 66.4 | -0.33 % | $ 4.59 B | USA |
 |
Agilent Technologies
A
|
1.62 B | $ 140.3 | 0.46 % | $ 42.7 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.48 | -2.65 % | $ 5.7 M | USA |
 |
Bioventus
BVS
|
304 M | $ 7.49 | -0.86 % | $ 469 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
170 M | $ 2.13 | 0.24 % | $ 540 M | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |